{
    "clinical_study": {
        "@rank": "63971", 
        "brief_summary": {
            "textblock": "To evaluate the safety of different doses and dosing regimens of tecogalan sodium (DS-4152)\n      and to establish the MTD at each of the different dosing schedules."
        }, 
        "brief_title": "A Phase I Trial of Tecogalan Sodium ( DS-4152 ) Administered as an Infusion Twice Weekly for 21 Days.", 
        "condition": [
            "Sarcoma, Kaposi", 
            "HIV Infections"
        ], 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome", 
                "Sarcoma, Kaposi", 
                "Sarcoma"
            ]
        }, 
        "detailed_description": {
            "textblock": "Patients receive intravenous DS-4152 by infusion twice weekly for 21 days, followed by 2\n      weeks of rest; courses may repeat. Patients undergo weekly follow-up. A punch biopsy will be\n      obtained from patients with Kaposi's sarcoma."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Patients must have:\n\n          -  Kaposi's sarcoma plus HIV infection OR metastatic solid tumor.\n\n          -  Life expectancy of at least 12 weeks.\n\n          -  NO symptomatic AIDS-defining opportunistic infection within the past 4 weeks.\n\n          -  Recovered from toxicity of any prior anticancer therapy.\n\n        Exclusion Criteria\n\n        Co-existing Condition:\n\n        Patients with the following symptoms or conditions are excluded:\n\n          -  Leukemia or lymphoma.\n\n          -  Current gastrointestinal bleeding by stool guaiac.\n\n          -  Extensive bone metastases or significant radiographic osteoporosis in patients with\n             solid tumors.\n\n          -  Active heart disease such as uncontrolled angina, uncompensated congestive heart\n             failure, or dysrhythmias requiring antiarrhythmics.\n\n          -  Acute intercurrent infection other than genital herpes.\n\n          -  Symptomatic or known central nervous system involvement (including brain metastases)\n             unless stable and off therapy.\n\n        Concurrent Medication:\n\n        Excluded:\n\n          -  Other anticancer therapy.\n\n          -  Other investigational agents.\n\n        Patients with the following prior conditions are excluded:\n\n          -  History of acute or chronic gastrointestinal bleeding or inflammatory bowel disease.\n\n          -  History of myocardial infarction within past 6 months.\n\n        Prior Medication:\n\n        Excluded:\n\n          -  Anticancer therapy within the past 3 weeks (6 weeks for nitrosourea or mitomycin C).\n\n          -  Investigational agents within the past 4 weeks."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002138", 
            "org_study_id": "088D", 
            "secondary_id": "4152A-PRT005"
        }, 
        "intervention": {
            "intervention_name": "Tecogalan sodium", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Antineoplastic Agents"
        }, 
        "keyword": [
            "Neoplasms", 
            "Sarcoma, Kaposi", 
            "Acquired Immunodeficiency Syndrome", 
            "Antineoplastic Agents", 
            "tecogalan"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": {
            "facility": {
                "address": {
                    "city": "San Francisco", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "94110"
                }, 
                "name": "Univ of California at San Francisco Gen Hosp"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "A Phase I Trial of Tecogalan Sodium ( DS-4152 ) Administered as an Infusion Twice Weekly for 21 Days.", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002138"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Daiichi Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Endpoint Classification: Safety Study, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 1996"
    }, 
    "geocoordinates": {
        "Univ of California at San Francisco Gen Hosp": "37.775 -122.419"
    }
}